T1	intervention 46 54	exercise
T2	total-participants 318 327	Forty-six
T3	eligibility 328 381	postmenopausal BCS (â‰¤Stage II, off primary treatment)
T5	control 436 449	control group
T15	outcome 1223 1246	PSQI daytime somnolence
T16	outcome 1272 1293	accelerometer latency
T17	outcome 1425 1443	Daytime somnolence
T18	outcome 1536 1547	interleukin
T19	outcome 1608 1615	fatigue
T4	condition 66 79	sleep quality
T14	outcome 1070 1089	PSQI sleep duration
T20	outcome 1373 1398	PSQI sleep duration score
T21	outcome 1402 1423	accelerometer latency
